L-2-(benzyloxy)-4-methylpentanoic acid | 108061-23-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: L-2-(benzyloxy)-4-methylpentanoic acid
• 英文别名: 4-Methyl-2-phenylmethoxypentanoic acid
• CAS: 108061-23-0
• 化学式: C₁₃H₁₈O₃
• 分子量: 222.284
• InChiKey: SKXDRVUWALIFFX-UHFFFAOYSA-N

物化性质

• 沸点：
  360.0±17.0 °C(Predicted)
• 密度：
  1.076±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  L-2-(benzyloxy)-4-methylpentanoic acid 在 草酰氯 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.33h， 生成 methyl (L-2-(benzyloxy)-4-methylpentanoyl)-L-alaninate
  参考文献：
  名称：

  Synthesis and chemical properties of tetrazole peptide analogs

  摘要：

  DOI：

  10.1021/jo00386a029
• 作为产物：
  描述：

  methyl L-2-(benzyloxy)-4-methylpentanoate 在 sodium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 以66%的产率得到L-2-(benzyloxy)-4-methylpentanoic acid
  参考文献：
  名称：

  Synthesis and chemical properties of tetrazole peptide analogs

  摘要：

  DOI：

  10.1021/jo00386a029

文献信息

• CARBOXYLIC ACID DERIVATIVES AND ADHESION MOLECULE INHIBITORS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
  申请人：TORAY INDUSTRIES, INC.

  公开号：EP1209147A1

  公开（公告）日：2002-05-29

  Prevention or therapy of inflammatory diseases caused by invasion of leukocytes such as monocytes, lymphocytes and eosinophils, by providing a substance which inhibits cell adhesion via an adhesion molecule, especially adhesion molecule VLA-4, is disclosed. A group of carboxylic acid derivatives represented by, for example, and adhesion molecule inhibitors comprising the same as an effective ingredient were provided.

  通过提供一种通过粘附分子抑制细胞粘附的物质，特别是粘附分子VLA-4，来预防或治疗由单核细胞、淋巴细胞和嗜酸性粒细胞侵袭引起的炎症性疾病的方法被揭示。提供了一组由羧酸衍生物代表的粘附分子抑制剂，例如，以其为有效成分的粘附分子抑制剂。
• [EN] BIOLOGICALLY ACTIVE COMPOUNDS<br/>[FR] COMPOSES A ACTIVITE BIOLOGIQUE
  申请人：AMURA THERAPEUTICS LTD

  公开号：WO2004007501A1

  公开（公告）日：2004-01-22

  Compounds of general formula (I) wherein: Z = CR3R4, where R3 and R4 are independently chosen from CO-7-alkyl P1 = CR5R6, P2 = O, CR7R8 or NR9, Y = CR10R11-C(O) or CR10R11-C(S) or CR10R11-S(O) or CR10R11-SO2 (X)o=.CR16R17 (W)n = 0, S, C(O), S(O) or S(O)2-or NR18 (V)m = C(O), C(S), S(O), S(O)2, S(O)2NH, OC(O), NHC(O), NHS(O), NHS(O)2, OC(O)NH, C(O)NH or CR19R20, C=N-C(O)-OR19 or C=N-C(O)-NHR19, U = a stable. 5- to 7-membered monocyclic or a stable 8- to 11-membered bicyclic ring which is either saturated or unsaturated, and which includes zero to four heteroatoms and their salts, hydrates, solvates, complexes and prodrugs are inhibitors of cathepsin K and other cysteine protease inhibitors and are useful as therapeutic agents, .for example in osteoporosis, Paget's disease gingival diseases such as gingivitis and periodontitis, hypercalaemia of malignancy, metabolic bone disease, diseases involving matrix or cartilage degradation, in particular osteoarthritis and rheumatoid arthritis and neoplastic diseases. The compounds are also useful for validating therapeutic target compounds.

  通式（I）的化合物中：其中：Z = CR3R4，其中R3和R4分别选择自CO-7-烷基P1 = CR5R6，P2 = O，CR7R8或NR9，Y = CR10R11-C（O）或CR10R11-C（S）或CR10R11-S（O）或CR10R11-SO2（X）o = .CR16R17（W）n = 0，S，C（O），S（O）或S（O）2-或NR18（V）m = C（O），C（S），S（O），S（O）2，S（O）2NH，OC（O），NHC（O），NHS（O），NHS（O）2，OC（O）NH，C（O）NH或CR19R20，C = N-C（O）-OR19或C = N-C（O）-NHR19，U = a stable。5-至7-成员单环或稳定的8-至11-成员双环，其饱和或不饱和，并包括零至四个杂原子及其盐、水合物、溶剂合物、络合物和前药是猫hepsin K和其他半胱氨酸蛋白酶抑制剂的抑制剂，并可用作治疗剂，例如在骨质疏松症、Paget病、牙龈疾病如牙龈炎和牙周炎、恶性高钙血症、代谢性骨病、涉及基质或软骨降解的疾病，特别是骨关节炎和类风湿性关节炎和肿瘤性疾病。这些化合物还可用于验证治疗靶点化合物。
• Inhibitors of cruzipain and other cysteine proteases
  申请人：——

  公开号：US20040106805A1

  公开（公告）日：2004-06-03

  Compounds of general formula (I): wherein R 1 , Y, (X) 0 , (W) n , (V) m , Z and U are as defined in the specification, are inhibitors of cruzipain and other cysteine protease inhibitors and are useful as therpeutic agents, for example in Chagas' disease, or for validating therapeutic target compounds. 1

  通式（I）的化合物：其中R1，Y，（X）0，（W）n，（V）m，Z和U如规范中定义，是克鲁齐帕因和其他半胱氨酸蛋白酶抑制剂的抑制剂，并且可用作治疗剂，例如在查加斯病中，或用于验证治疗靶点化合物。
• Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases
  申请人：——

  公开号：US20040127549A1

  公开（公告）日：2004-07-01

  Compounds of general formula (I), wherein R 1 , R 2 , R 3 , Y, (X) o , (W) n , (V) m , Z and U are as defined in the specification, are inhibitors of cruzipain and other cysteine protease inhibitors and are useful as therapeutic agents, for example in Chagas' disease, or for validating therapeutic target compounds. 1

  通式（I）的化合物，其中R1，R2，R3，Y，（X）o，（W）n，（V）m，Z和U的定义如规范所述，是cruzipain和其他半胱氨酸蛋白酶抑制剂的抑制剂，并且可用作治疗剂，例如在恶性贾格斯病中，或用于验证治疗靶向化合物。
• Process for producing optically active 3-(4-hydroxyphenyl)proprionic acids
  申请人：Yokozawa Tohru

  公开号：US20070142472A1

  公开（公告）日：2007-06-21

  The present invention relates to a process for producing an optically active 3-(4-hydroxyphenyl)propionic acid useful as intermediates for medicines, through short steps in good yield and with high optical purity. More specifically, the present invention relates to a process for producing an optically active 3-(4-hydroxyphenyl)propionic acid of the formula (6): wherein R 2 is an alkyl group; R 5 to R 8 are each independently a hydrogen atom or a substituent; and the symbol * is an chiral carbon atom, or a salt thereof, which comprises reacting a benzaldehyde of the formula (1): wherein R 1 is a protective group; and R 5 to R 8 are each the same as defined above, with a glycolic acid derivative of the formula (2): wherein R 3 is a hydrocarbon group; and R 2 is the same as defined above, hydrolyzing the resulting product to give a cinnamic acid of the formula (4): wherein R 1 , R 2 and R 5 to R 8 are each the same as defined above, or a salt thereof, and subjecting the resulting cinnamic acid (4) or a salt thereof to asymmetric hydrogenation to give an optically active phenylpropionic acid of the formula (5): wherein all the symbols are each the same as defined above, or a salt thereof, followed by deprotection.

  本发明涉及一种生产光学活性的3-(4-羟基苯基)丙酸的方法，该方法通过短步骤以良好产率和高光学纯度的方式，作为药物中间体。更具体地说，本发明涉及一种生产式(6)的光学活性3-(4-羟基苯基)丙酸的方法：其中R2是烷基；R5到R8分别独立地是氢原子或取代基；符号*是手性碳原子，或其盐，包括用式(1)的苯甲醛反应：其中R1是保护基；R5到R8分别与上述定义相同，与式(2)的乙二醇酸衍生物反应：其中R3是碳氢基团；R2与上述定义相同，水解所得产物得到式(4)的肉桂酸：其中R1、R2和R5到R8分别与上述定义相同，或其盐，并将所得的肉桂酸(4)或其盐经过不对称氢化作用得到式(5)的光学活性苯丙酸：其中所有符号均与上述定义相同，或其盐，然后去保护基。